Tag:
OTC
Latest Headlines
Latest Headlines
OraSure's OTC HIV test obtains crucial FDA panel backing
There isn't an approved over-the-counter home HIV diagnostic test yet. But OraSure stepped even closer to that milestone on Tuesday, when the FDA's Blood Products Advisory Committee voted unanimously to recommend approving the company's product.
Docs riled by FDA's proposal to open up drug access
The FDA would free up some treatments for chronic conditions, such as asthma and diabetes, so patients could obtain them without a prescription.
Fixing OTC production problems is a top priority for new J&J CEO
Resolving manufacturing problems so Johnson & Johnson can get its once well-regarded consumer brands back in consumers hands is Alex Gorsky's first priority as he officially takes the reins as CEO today.
FDA seeks advice on making more drugs OTC
The FDA is holding its second day of hearings on whether some prescription medications should become sold OTC.
GSK takes bids in European consumer-drug sale
GlaxoSmithKline ( $GSK ) is steaming ahead with its sale of consumer-drug brands. After unloading U.S. rights to a basket of products last year, the company accepted bids for European rights from...
FDA may let pharma sell more drugs without scripts
The FDA may let more drugs go OTC. Commissioner Margaret Hamburg says the agency is "trying to get feedback from various stakeholders" about improving access to medications. And one of...
GSK impatient to unload for-sale OTC brands
GlaxoSmithKline ( $GSK ) wants to make a deal already. After hawking a portfolio of consumer drugs for months, the company managed to unload 17 of them to Prestige Brands Holdings in December. Now, it
Novartis adds OTC drug plant to GMP fix list
Popular OTC drugs Excedrin, Theraflu, Triaminic and Maalox may become harder to find in the coming months, thanks to a voluntary manufacturing halt by Novartis ( $NVS ). The Lincoln, NE, plant shutdown
Report: GSK closing in on deal with Boston PE group for OTC assets
A Boston private equity group has pulled ahead in a contest to scoop up consumer health products from GlaxoSmithKline ( $GSK ), with a final deal in the works that could be revealed by the companies
HHS chief smacks down FDA's Plan B decision
Look for more hot debate about HHS Secretary Kathleen Sebelius' decision to trump the FDA on expanding access to the Plan B contraceptive. People are talking not only because it's about birth
